Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.

Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers

Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

ARTICLES

eGFR equations in the EHR—how lab met the request

October 2024—In patients at risk for chronic kidney disease, clinical practice guidelines released this year recommend the combined creatinine and cystatin C-based estimated glomerular filtration rate over the creatinine-based eGFR when cystatin C is available. “Cystatin C isn’t perfect itself, but a combination of the two seems to hit the sweet spot,” Angela Ferguson, PhD, D(ABCC), said in a session at the ADLM meeting in July. Dr. Ferguson is associate professor at the University of Missouri-Kansas City School of Medicine and co-director of clinical chemistry, director of immunology, and director of point-of-care testing in the Department of Pathology and Laboratory Medicine, Children’s Mercy Kansas City. The guidelines were released by the Kidney Disease: Improving Global Outcomes chronic kidney disease work group.

Can labs bridge the hematology data disconnect?

October 2024—Do clinicians understand how the technology in hematology has evolved and how laboratory data can help guide their decisions? It’s a question roundtable participants took on when they met online Aug. 29 with CAP TODAY publisher Bob McGonnagle. “There’s a disconnect with our clinical colleagues,” said Olga Pozdnyakova, MD, PhD, of the Hospital of the University of Pennsylvania. She and others spoke about solutions, instruments, AI, and reference ranges—in addition to the staffing shortage. “It is first and foremost in our minds,” Maria (Ria) Vergara-Lluri, MD, of Keck School of Medicine of USC, said of the ongoing shortage.

New Enhertu use, new HER2 complexities

September 2024—Every profession has its own news cycle. In pathology, the story arc is often a lengthy one, stretching from clinical triumph to Now what? Such is the case with expanded use of trastuzumab deruxtecan, which was granted accelerated FDA approval in late April for adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who received prior systemic treatment and have no alternative treatment options. Three multicenter trials evaluated the efficacy of the drug: DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02. PanTumor02 looked at seven tumor cohorts: endometrial, cervical, ovarian, bladder, biliary tract, pancreatic, and other solid cancers (excluding breast, colorectal, gastric, and non-small cell lung cancers). The results of these trials often were striking (median duration of response for PanTumor02 was 19.4 months, for example), and physicians are now looking closely at this tumor-agnostic (also referred to as tissue-agnostic) indication.

Intraop neuropathology consultation: tips and cases

September 2024—Leomar Ballester, MD, PhD, of the University of Texas MD Anderson Cancer Center has simple advice for those called to provide an intraoperative neuropathologic consultation: review the imaging and know the entities.

Self-collected vaginal swabs studied for HPV tests

September 2024—In HPV primary screening, self-collected vaginal samples enable accurate clinical HPV testing, and neither extended ambient dry storage nor exposure to extreme temperatures influence HPV detection, say the authors of a study published in June.

Host response solutions to sepsis risk prediction

September 2024—When emergency physician Chadd Kraus, DO, DrPH, of Lehigh Valley Health Network in Allentown, Pa., sees a patient who could have sepsis, he wants to know if there’s an infection and, if so, how bad it is based on the patient’s host response, what interventions are needed, and whether the patient will need to be hospitalized.

Eyes on LDT inventory and cyberattack readiness

September 2024—The ADLM meeting in Chicago had just wrapped up when Compass Group members met online Aug. 6 with CAP TODAY publisher Bob McGonnagle. Stan Schofield, Compass Group VP and managing principal, noted Allina Health had announced in late June its definitive agreement with Quest Diagnostics for select assets of Allina’s laboratory services business, and Schofield reported plenty of M&A talk at the ADLM meeting. The group’s August discussion began there and moved to laboratory-developed tests and cybersecurity.

A trio of magic potions to protect laboratories

September 2024—A “grimoire” for laboratories—that’s what J. Mark Tuthill, MD, of Henry Ford Health was asked to talk about at the Pathology Informatics Summit in May. Once he learned what the term meant, he got to work, and his book of magic for laboratories unfolded. He did not use a large language model to create his spells because “only a wizard” can teach such things, he said, which is why he consulted his 11-year-old grandson.

Tapping into the potential of urinalysis

September 2024—Tried and true but also having untapped potential is how three industry insiders see urinalysis. Though traditional urinalysis serves its purpose well, they say, it’s easy to envision the next level. “We tend to look at urinalysis with a fairly myopic view of counting particles and doing a dipstick,” says Jason Anderson, MPH, MT(ASCP), senior product manager for urinalysis solutions, Sysmex America. “So what becomes the definition of urinalysis in the future?” he asks. “When we look at blood, it isn’t plasma analysis, it isn’t serum analysis. It’s specific disease conditions, disciplines that use that fluid type. So I see urinalysis becoming a broader field in a sense that there has been a lack of research in urinalysis in general for some time and there’s huge capacity in a urine sample and an unmet need for better biomarkers.” This need, he says, spans the spectrum of diseases, not just renal diseases. “And those biomarkers, those metabolites, that are potentially useful in diagnosing various conditions can be found in urine.”

‘First of its kind’ update for cancer surveillance standards

September 2024—New cancer surveillance standards for tumor site, histology, and behavior code combinations and associated terms rolled out this year, after pathologists reviewed the combinations in an all-new effort. It’s an initiative known as Cancer PathCHART, short for Cancer Pathology Coding Histology and Registration Terminology, led by the National Cancer Institute with the support of 10 collaborating organizations, among them the CAP and the World Health Organization. “Nobody but the NCI could’ve done this. It’s been a great project,” says Kay Washington, MD, PhD, professor of pathology at Vanderbilt University Medical Center and a past member of the CAP Cancer Committee and American Joint Committee on Cancer.

MARKETPLACE

TRENDING